The dengue virus is a member of vector-borne diseases that causes zoonotic disease and spreads rapidly in the world. No single treatment or vaccine yet is available that is recommended and there is no correlation with protectiveness against this disease.
Introduction
The dengue virus is a vector-borne diseases that causes zoonotic disease and spreads rapidly in the world [1, 2] . No single treatment or vaccine is available that is recommended and there is no correlation with protectiveness against the disease. Neutralization tests were not able to distinguish between specific serotypes and crossimmune antibodies in patients at the onset of infection, which led to overestimation of the long-term serotype antibody response. Hybridoma and genetic engineering technologies can be used by utilizing and remodifying individual antibodies obtained from immunized individuals [3] .
The heavy chain (VH) and light chain (VL) variables are molecules of the immunoglobulin G (IgG) is the smallest part of the antibody. Although the part-time domain variable is short, it can be used as a long-term and rapid immune booster in the immune system.
Cell-based therapy has improved significantly over the last few decades and is poised to become a major pillar of modern medicine. Recent studies have shown that these cells have large immune modulation capacities [4] . Mesenchymal stem cells have immunomodulatory properties on some lineages such as T cells and B regulators.
Mesenchymal stem cell (MSC) has also been shown to possess extensive immunoregulation abilities and be able to cope with adaptive and innate immune responses. MSC inhibits proliferation and maturation of immune cells and suppresses immune reactions both in vitro and in vivo [5] .
Genetic stem cells can be modified to express intact antibody fragments or single chain antibody fragments (scFv) [6] . MSC has also has been investigated as a carrier medium for antibody delivery. In human MSC studies have been carried out nucleophysics to be able to express scFv on its cell surface against glioma III (EGFRvIII) [7] .
This platform is able to function to express a series of antigen-specific paratops.
In this study we tried to clone a coding gene that was able to influence the adaptive immune response to dengue 1-4 by using MSC as a gene carrier. Cellular response to dengue virus initiated MHC I and MHC II bonds on CD4 + and CD8 + T cells. Activation of some of these cytokines has a greater concentration in DHF patients. 
Material and methods

Construction and identification of IgG heavy chain genes
Adapted mice treated with multivalent dengue vaccination 1-4 and control were given PBS at a dose of 0.3 ml each, Injection was performed on days 0, 7, 14, 21 and 28. The spleen was taken on day 32 after being treated with five vaccinations. Then extracted RNA using Trizol (Invitrogen) and amplified with primers set GHVF and GHVR.
RNA extraction was performed using TRIzol® Reagent Invitrogen (Allen Way, USA).
Primer for PCR is designed using data from the National Center for Biotechnology The PCR product was detected by electrophoresis in 1% agarose gel. Target segments identified under Ultraviolet lights. Segment gene targets ligation and purification by using QIAquick Gel Extraction Kit.
Cloning scFv-IgG Gene
PCR Product coding scFv-IgG gene then sub Cloning using cassette vector pTA2, mixing on a 0.2 ml micro tube. 9 μl of the PCR product is fed into a 0. 
Transformation
The 
Result
To verify the genes we cloned can be integrated with the plasmid vector and have been transformed to competent E. coli, the plasmids were digest with HINDIII, the result of restriction was electrophoresis. MSC that has been transfected with the gene encoding scFv is expected to express scFv-IgG on its cell surface, so can produce IgG. MSC is a unique multipotent stem cell, currently widely exploited as a vector for gene therapy, including for cancer and autoimmune diseases [8] [9] [10] [10] [11] [12] [13] .
MSC is easy to transfection with certain protein-coding plasmids either temporary or long-term and stable. The transduced MSC can produce more IL-10 to produce collagen to suppress arthritis in mouse models [15] . MSC immunoregulation also depends on 
Conclusion
The scFv gene encoding IgG can be integrated with MSC. The modified MSC to express scFv-IgG on its cell surface is expected to respond quickly to antigen specific to scFvIgG. The idea for the use of MSC to express scFv-IgG against denv-1, 2, 3 and 4. Specifically, the potential of MSC as an immune therapy medium is remarkable, therefore a deep evaluation is needed for its effectiveness.
Although some studies have proven that MSC is very effective for expressing and secreting immune therapy. Analysis of the impact of specific immunity to target organs, including humoral and cellular responses of memory cells.
